<DOC>
	<DOCNO>NCT01054638</DOCNO>
	<brief_summary>Cardiovascular disease ( CVD ) associate HIV infection . However , uncertain whether increased CVD rate associate HIV-related factor ( e.g. , HIV-infection highly active antiretroviral therapy ( HAART ) may worsen dyslipidemia ) reflect difference prevalence underlie risk factor CVD . Furthermore , association initiation duration HAART exposure CVD risk , include specific drug within HAART class may contribute increase risk , unknown . The primary objective study therefore : 1 . To estimate absolute relative incidence rate ( IR ) CVD claims-based diagnosis among cohort adult patient large manage care population claim diagnosis HIV , AIDS , AIDS-related complex ( ARC ) period exposure : - Any HAART compare HAART exposure - HAART class [ i.e. , NRTIs , NNRTIs , PIs , Other ( i.e. , fusion inhibitor ) ] compare HAART class exposure - Specific NRTI medication compare specific NRTI exposure</brief_summary>
	<brief_title>HIV Treatment CVD Events</brief_title>
	<detailed_description>The scientific approach conduct retrospective cohort study patient claim diagnosis HIV , AIDS , ARC ( simply refer HIV infection ) among commercially insured people U.S. estimate IR acute MI ( AMI ) , AMI include coronary revascularization ( CR ) procedure , CVD , compare exposure HAART treatment . We identify primary cohort patient initial claim diagnosis HIV infection occur least 6 month continuous enrollment Ingenix National Health Informatics ( NHI ) Ingenix Impact National Managed Care ( Impact ) Databases 01 January 1998 31 December 2007 . For eligible primary cohort member , identify HAART dispensings baseline follow-up period categorize person-time exposure HAART , HAART class , specific NRTI medication . We also specifically evaluate risk associate fosamprenavir amprenavir use . Study outcome event , include AMI , AMI include CR procedure , CVD , identify medical claim data patient follow-up period . For primary analysis , estimate absolute IR 95 % confidence interval ( CIs ) study outcome event period recent , past , non-use , cumulative duration ( non-use , &lt; 1 year , 1 - 2 year , &gt; 2 year ) HAART exposure classification . We also estimate rate difference ( RD ) 95 % CI study outcome event period recent , past , cumulative duration ( &lt; 1 year , 1 - 2 year , &gt; 2 year ) HAART exposure classification relative non-use . We use Poisson regression model estimate multivariable adjusted rate ratio ( RR ) 95 % CIs study outcome event period recent , past , cumulative duration ( non-use , &lt; 1 year , 1 - 2 year , &gt; 2 year ) HAART use relative non-use HAART exposure classification , adjust confound variable derive claim history person 6-month baseline period account channel bias follow-up period account change risk factor CVD . To account confound indication abacavir use , analysis stratify calendar year 2004 , time significant change primary indication abacavir use HIV . Analyses repeat secondary analysis subgroup patient NHI Database outpatient laboratory test result ; analyse account value cholesterol , cluster differentiation 4 ( CD4 ) count , viral load [ HIV-1 ribonucleic acid ( RNA ) ] laboratory test . Among primary cohort , identify subcohort patient initial claim diagnosis HIV infection occur least 6 month continuous enrollment without HAART medication 6-month baseline period prior cohort entry date . We repeat primary secondary analysis among na√Øve subcohort HAART initiator . ViiV Healthcare new sponsor study , GlaxoSmithKline process update system reflect change sponsorship .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<criteria>All patient age 18 year old initial claim diagnosis HIV infection associate physician visit occur least 6 month ( 183 day ) continuous enrollment 01 January 1998 31 December 2007 include primary cohort . Patients required commercial health insurance coverage complete medical pharmacy benefit . The cohort entry date patient limit first claim associate HIV infection diagnosis meet 6month continuous enrollment criterion . Patients HIV infection diagnosis claim least one continuously enrol segment equal great 6 month prior cohort entry date exclude . Six month continuous enrollment prior initial claim associate HIV infection diagnosis require guarantee availability 6month baseline period ascertain exposure HAART prior cohort entry covariates interest Poisson regression model . Patients may enter primary cohort already expose HAART HIV infection diagnosis claim 6month baseline period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>amprenavir</keyword>
	<keyword>fosamprenavir</keyword>
	<keyword>HIV</keyword>
	<keyword>HAART treatment</keyword>
	<keyword>Epzicom</keyword>
	<keyword>Trizivir</keyword>
	<keyword>Combivir</keyword>
	<keyword>zidovudine</keyword>
	<keyword>lamivudine</keyword>
	<keyword>cardiovascular disease</keyword>
	<keyword>HIV Infections</keyword>
</DOC>